27414-25-1 Usage
Appearance
Pale yellow powder This describes the physical appearance of the compound, which is a pale yellow powder.
Derivative of indazole
This indicates that the compound is derived from the indazole structure.
Contains a nitro group and an ethanol group
This indicates that the compound contains a nitro group (-NO2) and an ethanol group (-CH2CH3) which makes it a nitroalkanol compound.
Commonly used in the synthesis of pharmaceuticals and organic compounds
This indicates that the compound is used as a building block in the synthesis of other chemical compounds, particularly in the pharmaceutical and organic chemistry fields.
Used as an intermediate in the production of dyes and pigments
This indicates that the compound is used as a reactant in the production of dyes and pigments, typically as an intermediate in a multi-step synthesis.
Potentially reactive due to the presence of the nitro group
This indicates that the compound may undergo certain chemical reactions due to the presence of the nitro group and should be handled with care.
Check Digit Verification of cas no
The CAS Registry Mumber 27414-25-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,4,1 and 4 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 27414-25:
(7*2)+(6*7)+(5*4)+(4*1)+(3*4)+(2*2)+(1*5)=101
101 % 10 = 1
So 27414-25-1 is a valid CAS Registry Number.
27414-25-1Relevant academic research and scientific papers
1-((S)-2-aminopropyl)-1H-indazol-6-ol: A potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity
May, Jesse A.,Dantanarayana, Anura P.,Zinke, Paul W.,McLaughlin, Marsha A.,Sharif, Najam A.
, p. 318 - 328 (2007/10/03)
Serotonin 5-HT2 receptor agonists have been identified as a potential new class of agents for the treatment of ocular hypertension and glaucoma. The initially reported tryptamine analogues displayed either poor solution stability, potent centra
